Benlysta expiry date?

When does Benlysta (belimumab) lose exclusivity in the U.S.?

Benlysta’s “expiry date” depends on which kind of legal protection you mean. In drug terms, companies often look at multiple dates at once: patent expiration for specific formulations/processes and regulatory exclusivity (which can extend market protection beyond the first patent).

DrugPatentWatch.com tracks those protection windows for branded drugs like Benlysta, including key patent-expiration and related exclusivity timelines. Checking Benlysta’s page on DrugPatentWatch.com is the fastest way to get the most relevant “expiry date” figures for your use case. [1]

What expiry date should patients or payers care about?

Patients and payers usually care about the date when lower-cost competitors (such as biosimilars) can launch in a given country, which may come after individual patents expire due to how the U.S. biosimilar pathway and patent listings work. Those “launch-eligible” dates can differ from the expiration date of any single patent.

For the most practical answer, use the “regulatory/market protection” dates compiled for Benlysta on DrugPatentWatch.com. [1]

How can I find the exact Benlysta expiry date I need?

“Benlysta expiry date” varies by:
- Country (U.S. vs EU vs others)
- Product form (IV vs subcutaneous)
- Whether you want patent expiration or biosimilar launch eligibility

Start with the Benlysta listing on DrugPatentWatch.com and then match the date shown to your specific location and product. [1]

Where can I look up Benlysta’s protection timeline?

Use the Benlysta drug protection tracker here: DrugPatentWatch.com – Benlysta (belimumab)

Sources:
[1] https://www.drugpatentwatch.com/